Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Polysubstance Use: A Broader Understanding of Substance Use During the Opioid Crisis.

Cicero TJ, Ellis MS, Kasper ZA.

Am J Public Health. 2020 Feb;110(2):244-250. doi: 10.2105/AJPH.2019.305412. Epub 2019 Dec 19.

2.

The impact of opioid use disorder on levels of educational attainment: Perceived benefits and consequences.

Ellis MS, Kasper ZA, Cicero TJ.

Drug Alcohol Depend. 2020 Jan 1;206:107618. doi: 10.1016/j.drugalcdep.2019.107618. Epub 2019 Nov 2.

PMID:
31757520
3.

An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user.

Buttram ME, Kurtz SP, Cicero TJ, Havens JR.

Drug Alcohol Depend. 2019 Nov 1;204:107554. doi: 10.1016/j.drugalcdep.2019.107554. Epub 2019 Sep 13.

PMID:
31542629
4.

Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.

Buttram ME, Kurtz SP, Ellis MS, Cicero TJ.

J Subst Abuse Treat. 2019 Oct;105:1-4. doi: 10.1016/j.jsat.2019.07.011. Epub 2019 Jul 21.

PMID:
31443885
5.

Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.

Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, Roland CL, Schnoll SH, Webster LR, Park PW.

Postgrad Med. 2019 Apr;131(3):225-229. doi: 10.1080/00325481.2019.1585688. Epub 2019 Mar 19.

PMID:
30794760
6.

Understanding multi-pill ingestion of prescription opioids: Prevalence, characteristics, and motivation.

Ellis MS, Cicero TJ, Dart RC, Green JL.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):117-121. doi: 10.1002/pds.4687. Epub 2018 Nov 9.

PMID:
30411819
7.

Understanding the use of diverted buprenorphine.

Cicero TJ, Ellis MS, Chilcoat HD.

Drug Alcohol Depend. 2018 Dec 1;193:117-123. doi: 10.1016/j.drugalcdep.2018.09.007. Epub 2018 Oct 12.

8.

Twin epidemics: The surging rise of methamphetamine use in chronic opioid users.

Ellis MS, Kasper ZA, Cicero TJ.

Drug Alcohol Depend. 2018 Dec 1;193:14-20. doi: 10.1016/j.drugalcdep.2018.08.029. Epub 2018 Oct 10.

PMID:
30326396
9.

Is a Reduction in Access to Prescription Opioids the Cure for the Current Opioid Crisis?

Cicero TJ.

Am J Public Health. 2018 Oct;108(10):1322-1323. doi: 10.2105/AJPH.2018.304648. No abstract available.

PMID:
30207773
10.

Increased use of heroin as an initiating opioid of abuse: Further considerations and policy implications.

Cicero TJ, Kasper ZA, Ellis MS.

Addict Behav. 2018 Dec;87:267-271. doi: 10.1016/j.addbeh.2018.05.030. Epub 2018 May 31.

PMID:
30006021
11.

Oral and non-oral routes of administration among prescription opioid users: Pathways, decision-making and directionality.

Cicero TJ, Ellis MS.

Addict Behav. 2018 Nov;86:11-16. doi: 10.1016/j.addbeh.2018.05.015. Epub 2018 May 22. No abstract available.

PMID:
29807800
12.

Do abuse deterrent opioid formulations work?

Dart RC, Iwanicki JL, Dasgupta N, Cicero TJ, Schnoll SH.

J Opioid Manag. 2017 Nov/Dec;13(6):365-378. doi: 10.5055/jom.2017.0415. Review.

PMID:
29308584
13.
14.

Abuse-deterrent Opioid Formulations.

Litman RS, Pagán OH, Cicero TJ.

Anesthesiology. 2018 May;128(5):1015-1026. doi: 10.1097/ALN.0000000000002031. Review.

PMID:
29252508
15.

Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.

Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, Green JL.

J Pain. 2018 Apr;19(4):439-453. doi: 10.1016/j.jpain.2017.11.007. Epub 2017 Dec 7.

PMID:
29224919
16.

Tissue-specific DNA methylation is conserved across human, mouse, and rat, and driven by primary sequence conservation.

Zhou J, Sears RL, Xing X, Zhang B, Li D, Rockweiler NB, Jang HS, Choudhary MNK, Lee HJ, Lowdon RF, Arand J, Tabers B, Gu CC, Cicero TJ, Wang T.

BMC Genomics. 2017 Sep 12;18(1):724. doi: 10.1186/s12864-017-4115-6.

17.

Heroin use onset among nonmedical prescription opioid users in the club scene.

Surratt HL, Kurtz SP, Buttram M, Levi-Minzi MA, Pagano ME, Cicero TJ.

Drug Alcohol Depend. 2017 Oct 1;179:131-138. doi: 10.1016/j.drugalcdep.2017.06.034. Epub 2017 Jul 26.

18.

Increases in self-reported fentanyl use among a population entering drug treatment: The need for systematic surveillance of illicitly manufactured opioids.

Cicero TJ, Ellis MS, Kasper ZA.

Drug Alcohol Depend. 2017 Aug 1;177:101-103. doi: 10.1016/j.drugalcdep.2017.04.004. Epub 2017 May 30.

PMID:
28582697
19.

Increased use of heroin as an initiating opioid of abuse.

Cicero TJ, Ellis MS, Kasper ZA.

Addict Behav. 2017 Nov;74:63-66. doi: 10.1016/j.addbeh.2017.05.030. Epub 2017 May 23.

PMID:
28582659
20.

Understanding the demand side of the prescription opioid epidemic: Does the initial source of opioids matter?

Cicero TJ, Ellis MS.

Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S4-S10. doi: 10.1016/j.drugalcdep.2016.03.014.

21.

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.

Iwanicki JL, Severtson SG, McDaniel H, Rosenblum A, Fong C, Cicero TJ, Ellis MS, Kurtz SP, Buttram ME, Dart RC.

PLoS One. 2016 Dec 9;11(12):e0167499. doi: 10.1371/journal.pone.0167499. eCollection 2016.

22.

Reply.

Cicero TJ, Ellis MS, Kasper ZA.

Pain. 2016 Dec;157(12):2875-2876. No abstract available.

PMID:
27841841
23.

Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.

Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, BucherBartelson B, Green JL, Dart RC.

Drug Alcohol Depend. 2016 Nov 1;168:219-229. doi: 10.1016/j.drugalcdep.2016.09.018. Epub 2016 Oct 3.

24.

Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers.

Cicero TJ, Ellis MS, Kasper ZA.

Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):56-62. doi: 10.1002/pds.4078. Epub 2016 Sep 4.

PMID:
27594167
25.

Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers.

Cicero TJ, Ellis MS, Kasper ZA.

Addict Behav. 2017 Feb;65:242-244. doi: 10.1016/j.addbeh.2016.08.024. Epub 2016 Aug 15.

PMID:
27544696
26.

No End in Sight: The Abuse of Prescription Narcotics.

Cicero TJ.

Cerebrum. 2015 Sep 1;2015. pii: cer-11-15. eCollection 2015 Sep-Oct.

27.

A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.

Cicero TJ, Ellis MS, Kasper ZA.

Pain. 2016 Jun;157(6):1232-8. doi: 10.1097/j.pain.0000000000000511.

PMID:
27186712
28.

Nonmedical Prescription-Opioid Use and Heroin Use.

Cicero TJ, Ellis MS.

N Engl J Med. 2016 Mar 31;374(13):1295-6. doi: 10.1056/NEJMc1601875. No abstract available.

PMID:
27028931
29.

Shifting Patterns of Prescription Opioid and Heroin Abuse in the United States.

Cicero TJ, Ellis MS, Harney J.

N Engl J Med. 2015 Oct 29;373(18):1789-90. doi: 10.1056/NEJMc1505541. No abstract available.

30.

Abuse Deterrent Formulations of Prescription Opioids--Reply.

Cicero TJ, Ellis MS.

JAMA Psychiatry. 2015 Aug;72(8):850-1. doi: 10.1001/jamapsychiatry.2015.0674. No abstract available.

PMID:
26153921
31.

Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

Cicero TJ, Ellis MS.

JAMA Psychiatry. 2015 May;72(5):424-30. doi: 10.1001/jamapsychiatry.2014.3043.

PMID:
25760692
32.

Trends in opioid analgesic abuse and mortality in the United States.

Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL.

N Engl J Med. 2015 Jan 15;372(3):241-8. doi: 10.1056/NEJMsa1406143.

33.

Anticipated and unanticipated consequences of abuse deterrent formulations of opioid analgesics.

Cicero TJ, Ellis MS.

Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):205-7. doi: 10.1002/pds.3732. Epub 2014 Dec 16. No abstract available.

PMID:
25511763
34.

Driven by prescription drug abuse, heroin use increases among suburban and rural whites.

Cicero TJ, Kuehn BM.

JAMA. 2014 Jul;312(2):118-9. doi: 10.1001/jama.2014.7404. No abstract available.

PMID:
25005636
35.

Factors contributing to the rise of buprenorphine misuse: 2008-2013.

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP.

Drug Alcohol Depend. 2014 Sep 1;142:98-104. doi: 10.1016/j.drugalcdep.2014.06.005. Epub 2014 Jun 18.

PMID:
24984689
36.

Pain treatment and antiretroviral medication adherence among vulnerable HIV-positive patients.

Surratt HL, Kurtz SP, Levi-Minzi MA, Cicero TJ, Tsuyuki K, O'Grady CL.

AIDS Patient Care STDS. 2015 Apr;29(4):186-92. doi: 10.1089/apc.2014.0104. Epub 2014 Jul 1.

37.

The changing face of heroin use in the United States: a retrospective analysis of the past 50 years.

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP.

JAMA Psychiatry. 2014 Jul 1;71(7):821-6. doi: 10.1001/jamapsychiatry.2014.366.

PMID:
24871348
38.

Abuse and diversion of buprenorphine sublingual tablets and film.

Lavonas EJ, Severtson SG, Martinez EM, Bucher-Bartelson B, Le Lait MC, Green JL, Murrelle LE, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC.

J Subst Abuse Treat. 2014 Jul;47(1):27-34. doi: 10.1016/j.jsat.2014.02.003. Epub 2014 Mar 3.

39.

Reductions in prescription opioid diversion following recent legislative interventions in Florida.

Surratt HL, O'Grady C, Kurtz SP, Stivers Y, Cicero TJ, Dart RC, Chen M.

Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):314-20.

PMID:
24677496
40.

Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States.

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP.

Pain. 2013 Dec;154(12):2639-48. doi: 10.1016/j.pain.2013.07.025.

PMID:
24287106
41.

Antiretroviral medication diversion among HIV-positive substance abusers in South Florida.

Surratt HL, Kurtz SP, Cicero TJ, O'Grady C, Levi-Minzi MA.

Am J Public Health. 2013 Jun;103(6):1026-8. doi: 10.2105/AJPH.2012.301092. Epub 2013 Apr 18.

42.

Witnessed versus unwitnessed random urine tests in the treatment of opioid dependence.

Mallya A, Purnell AL, Svrakic DM, Lovell AM, Freedland KE, Gott BM, Sayuk GS, Cicero TJ, Brawer PA, Trafton JA, Scherrer JF, Lustman PJ.

Am J Addict. 2013 Mar-Apr;22(2):175-7. doi: 10.1111/j.1521-0391.2013.00326.x.

43.

Assessment of the abuse of tapentadol immediate release: the first 24 months.

Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH.

J Opioid Manag. 2012 Nov-Dec;8(6):395-402. doi: 10.5055/jom.2012.0139.

PMID:
23264317
44.

Health outcomes in patients using no-prescription online pharmacies to purchase prescription drugs.

Cicero TJ, Ellis MS.

J Med Internet Res. 2012 Dec 6;14(6):e174. doi: 10.2196/jmir.2236.

45.

Effect of abuse-deterrent formulation of OxyContin.

Cicero TJ, Ellis MS, Surratt HL.

N Engl J Med. 2012 Jul 12;367(2):187-9. doi: 10.1056/NEJMc1204141. No abstract available.

46.

Multiple Determinants of Specific Modes of Prescription Opioid Diversion.

Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, Inciardi JA.

J Drug Issues. 2011 Spring;41(2):283-304.

47.

Alternate routes of administration and risk for HIV among prescription opioid abusers.

Surratt H, Kurtz SP, Cicero TJ.

J Addict Dis. 2011 Oct;30(4):334-41. doi: 10.1080/10550887.2011.609805.

48.

Elevated levels of DNA methylation at the OPRM1 promoter in blood and sperm from male opioid addicts.

Chorbov VM, Todorov AA, Lynskey MT, Cicero TJ.

J Opioid Manag. 2011 Jul-Aug;7(4):258-64.

49.

Patterns of prescription opioid abuse and comorbidity in an aging treatment population.

Cicero TJ, Surratt HL, Kurtz S, Ellis MS, Inciardi JA.

J Subst Abuse Treat. 2012 Jan;42(1):87-94. doi: 10.1016/j.jsat.2011.07.003. Epub 2011 Aug 9.

50.

Role of key informants and direct patient interviews in epidemiological studies of substance abuse.

Cicero TJ, Ellis MS, Paradis A, Ortbal Z.

Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):308-12. doi: 10.1002/pds.2075. Epub 2010 Dec 9.

Supplemental Content

Loading ...
Support Center